Social Icons

Showing posts with label Free Commodity Tips. Show all posts
Showing posts with label Free Commodity Tips. Show all posts

Wednesday 29 August 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 29 August 2018

capitalstars

CS OPENING BELL:
NIFTY SPOT DOWN 5@11732
SENSEX SPOT UP 3@38899
BANK NIFTY FUTURES UP 8@ 28396
HAPPY TRADING!


CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH
RES2: 11810
RES 1:11740
SUP1:11600
SUP2:11530


CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BULLISH
RES 2: 28860
RES 1: 28600
SUP1: 28100
SUP2: 27920


visit us: www.capitalstars.com/

call us:

9977499927
7440449744

Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.


Friday 15 June 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CAPITALSTARS-CORPORATE NEWS


capitalstars

Dr. Reddy's launches gSuboxone
Dr Reddy Lab Dr. Reddy's Laboratories has announced that it is launching generic of Buprenorphine and Naloxone Sublingual Film (Suboxone) following a final USFDA approval in the US market.
The product is being launched with USFDA’s approved Risk Evaluation and Mitigation Strategy (REMS) Program. US Company, Mylan has also launched this drug in the US market. Considering that the patent on this drug is still valid, this is at risk launch.
Buprenorphine and naloxone are used to treat adults with opioid dependence/addiction. The combination of these medications is used as part of a complete treatment program including prescription monitoring, counselling, and psychosocial support. The launch has been very important as per the USFDA’s recent statements indicating increasing opioid addiction in America.

Maruti Suzuki likely to bid adieu to Ignis Diesel variant
India’s largest passenger vehicle (PV) manufacturer Maruti Suzuki India Limited (MSIL) is likely to stop production of diesel variant of its hatchback Ignis, as per media reports. The Ignis was launched in January 2017 with both variants – petrol and diesel. While the petrol variant will be retained, diesel version will be likely discontinued. Several reasons could be responsible for the decision.
Firstly, the steep pricing proved to be a deterrent. While the petrol Ignis is priced between Rs4.66Lakh and Rs6.51Lakh, the diesel variant ranges between Rs6.32Lakh and Rs8.12Lakh (ex-showroom price in New Delhi as per website www.cardekho.com). Secondly, consumers are increasingly sceptical of owning diesel cars given that price difference between diesel and petrol in the retail market (fuel pumps) is narrowing. As per media reports, about 90% of Ignis models sold so far have been petrol variants and only 10% have been diesel variants. Lastly, it makes more sense for MSIL to free up capacity for its best-selling models rather than continuing with laggards.

Avanti Feeds surges after shareholders approve stock split
Avanti Feeds registered gains at the equity market after it announced its decision to sub-divide equity shares from face value of Rs2 each to Rs1 each. Further, it decided to issue bonus equity shares of Rs1 each in the ratio of 1:2, that is, one equity share of Rs1 each for every two and equity shares of Rs1 each (after sub-division of shares). Shareholders approved this recommendation with the requisite majority.This could be good news for the company.
The company is a leading manufacturer and exporter of shrimp feeds and shrimp processor. It also operates wind mill with an installed capacity of ~3.2 megawatt in Karnataka. It derived ~83% revenue from shrimp feeds and ~17% revenue from processed shrimp during FY18. The total feed capacity stands at six lakh tonnes per annum as on March 31, 2018.

Alembic Pharma rises on getting EIR from USFDA for Panelav unit
Alembic Pharmaceuticals Alembic Pharmaceuticals is currently trading at Rs520.35 up by Rs13.8 or 2.72% from its previous closing of Rs506.55 on the BSE. The pharma company said it received establishment inspection report (EIR) from USFDA for the inspection carried out by them at the company’s formulation facility at Panelav during the period from March 1, 2018 to March 20, 2018.
On Thursday, the firm announced during trading hours that day that it has received approval from USFDA for its ANDA for Doxycycline Hyclate capsules USP, 50mg and 100mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vibramycin capsules, 50mg and 100mg, of Pfizer Inc.

NBCC bags contracts worth Rs480.6cr in May
NBCC NBCC (India) is currently trading at Rs85.50 up by Rs0.2 or 0.23% from its previous closing of Rs85.30 on the BSE.
The company has secured the total business of Rs480.65cr (approx) in the month of May, 2018.
NBCC is a Navratna PSU engaged in the business of project management consultancy (PMC), real estate and EPC. PMC and redevelopment comprises 87%, real estate and EPC forms 13% of the company’s order book. Through PMC, the company has been executing many landmark projects.


visit us: www.capitalstars.com/


call on:9977499927

O731-6690000

Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647



Saturday 20 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CapitalStars On CNBC Awaaz, Kamyabi Ki Raah - 20 Jan 2018

CapitalStars On CNBC Awaaz, Kamyabi Ki Raah - 20 Jan 2018


CapitalStars Award Winning, SEBI registered, ISO certified investment advisory company. We provide intraday & positional services in equity , derivative ,commodity & currency. Our research team is highly skilled & experienced 

Contact Us 0731-6690000.

CLICK HERE FOR GET DETAILS & JOIN OUR BEST ADVISORY  -
 CAPITALSTARS CALL US  9977499927
Equity Tips , Intraday Stock Tips , FreeTrading Tips  , Sebi Registered advisory Company , Capitalstars Video Gallery

Investment  & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

 

Do U Want !!!!

Our Special Services

sensex-nifty-charts

 
Blogger Templates